Akeso (SEHK:9926) Unveils Promising Data For IO-Resistant Lung Cancer Therapy

Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC

HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC were presented in a Mini…

Akeso (SEHK:9926) Unveils Promising Data For IO-Resistant Lung Cancer Therapy

Akeso (SEHK:9926) recently captured attention by presenting promising data on its cadonilimab therapy at the World Conference on Lung Cancer, highlighting its potential as a breakthrough treatment for immunotherapy-resistant non-small cell lung cancer. Over the last quarter, the company's share price surged 40%, potentially influenced by these significant clinical developments and the awarding of Breakthrough Therapy Designation. The broader mar…